BML Capital Management’s Oruka Therapeutics ORKA Stock Holding History

BML Capital Management’s Portfolio ORKA Stock Details ORKA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q2	–	Sell	-58,911	Closed	-$1.24M	–	32
2024 Q1	$1.24M	Hold	58,911	–	–	0.82%	20
2023 Q4	$1.2M	Hold	58,911	–	–	0.91%	21
2023 Q3	$1.42M	Hold	58,911	–	–	1.3%	12
2023 Q2	$1.44M	Hold	58,911	–	–	1.29%	17
2023 Q1	$1.41M	Sell	58,911 -12,610	-18%	-$332K	1.22%	20
2022 Q4	$2.03M	Buy	+71,521	New	+$1.83M	1.94%	15

Other funds holding ORKA

CCC

Cable Car Capital San Francisco, California $4.66B AUM 77.16% 1-Year Est. Return

RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return

Janus Henderson Group London $209B AUM 37.72% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return

APM

Avidity Partners Management Dallas, Texas $624M AUM 250.2% 1-Year Est. Return

VR Adviser New York $3.3B AUM 525.74% 1-Year Est. Return

CAC

Cowen and Company New York $2.97B AUM 105.26% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Commodore Capital New York $1.68B AUM 375.52% 1-Year Est. Return

BML Capital Management's ORKA Position: Q2 2024 in Review

BML Capital Management sold out of Oruka Therapeutics (ORKA) in Q2 2024, closing a stake of 58,911 shares — an estimated $1.24M sold.

BML Capital Management first reported a position in ORKA in Q4 2022 and held it in 6 quarters. The position peaked at $2.03M in Q4 2022. 31 funds tracked by Wall St. Rank hold ORKA as of Q2 2024.

BML Capital Management reported no remaining Oruka Therapeutics position as of Q2 2024 after selling out during the quarter.
BML Capital Management sold 58,911 Oruka Therapeutics shares in Q2 2024, an estimated $1.24M.
BML Capital Management first reported a position in Oruka Therapeutics in Q4 2022 and held it in 6 quarters.
BML Capital Management's Oruka Therapeutics position peaked at $2.03M in Q4 2022.
31 funds tracked by Wall St. Rank held Oruka Therapeutics as of Q2 2024.

Based on BML Capital Management's 13F filing for Q2 2024, filed 7 Aug 2024.